Q1. Should an extended red cell antigen profile be obtained by genotype or serology vs only ABO/RhD type for patients with SCD? |
Q2. Should prophylactic Rh (C, E, or C/c, E/e)- and K-matched red cells or prophylactic Rh (C, E or C/c, E/e)-matched, K-matched, and extended matched (Jka/Jkb, Fya/Fyb, S/s) red cells, by serologic or genotype-predicted red cell antigen profile, vs only ABO/RhD-matched red cells be used for patients with SCD receiving transfusions? |
Q3. Should immunosuppressive therapy (IVIg, steroids, and/or rituximab) vs no immunosuppressive therapy be used for patients with SCD (all genotypes) with an acute need for transfusion and with a high risk for HTR? |
Q4. Should immunosuppressive therapy (IVIg, steroids, rituximab, and/or eculizumab) vs no immunosuppressive therapy be used for patients with SCD (all genotypes) with ongoing hyperhemolysis (defined as rapid decline of posttransfusion hemoglobin to below the pretransfusion level)? |
Q5. Should automated RCE vs simple transfusion or manual RCE be used for patients with SCD receiving chronic transfusions? |
Q6. Should automated or manual RCE be used over simple transfusion for patients with SCD and severe acute chest syndrome? |
Q7. Should red cell exchange with IHD-RCE vs conventional RCE be used for patients with SCD receiving chronic transfusions? |
Q8. Should prophylactic transfusion at regular intervals vs standard care (transfusion only when indicated for a complication or exacerbated anemia) be provided to pregnant patients with SCD? |
Q9. Should preoperative transfusion vs no preoperative transfusion be used for patients with SCD undergoing surgeries requiring general anesthesia and lasting longer than 1 h? |
Q10a. Should iron overload screening by MRI for liver iron content vs serial monitoring of ferritin levels alone be used for patients with SCD receiving chronic transfusion therapy? |
Q10b. Should iron overload screening by MRI for cardiac iron content vs serial monitoring of ferritin levels alone be used for patients with SCD receiving chronic transfusion therapy? |